Price T Rowe Associates Inc. MD Grows Stake in REGENXBIO Inc. (NASDAQ:RGNX)

Price T Rowe Associates Inc. MD boosted its position in REGENXBIO Inc. (NASDAQ:RGNX) by 9.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,910 shares of the biotechnology company’s stock after purchasing an additional 1,982 shares during the period. Price T Rowe Associates Inc. MD’s holdings in REGENXBIO were worth $185,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in REGENXBIO in the 4th quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd purchased a new position in REGENXBIO during the fourth quarter worth $79,000. Teacher Retirement System of Texas increased its position in REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after buying an additional 2,088 shares in the last quarter. EntryPoint Capital LLC purchased a new position in REGENXBIO during the fourth quarter worth $97,000. Finally, Tower Research Capital LLC TRC increased its position in REGENXBIO by 442.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company’s stock worth $102,000 after buying an additional 10,714 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at REGENXBIO

In related news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the transaction, the director now owns 475,103 shares in the company, valued at approximately $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.79% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. HC Wainwright dropped their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, Leerink Partners set a $24.00 price target on REGENXBIO in a research report on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.63.

REGENXBIO Stock Up 2.9%

Shares of NASDAQ:RGNX opened at $8.89 on Friday. The company has a market cap of $445.92 million, a P/E ratio of -1.77 and a beta of 1.11. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $16.25. The business has a fifty day simple moving average of $7.54 and a 200-day simple moving average of $7.98.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $89.01 million during the quarter, compared to analysts’ expectations of $105.35 million. Sell-side analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.